| First Author | Dibra D | Year | 2024 |
| Journal | Sci Adv | Volume | 10 |
| Issue | 7 | Pages | eadk1835 |
| PubMed ID | 38354236 | Mgi Jnum | J:345286 |
| Mgi Id | MGI:7594984 | Doi | 10.1126/sciadv.adk1835 |
| Citation | Dibra D, et al. (2024) Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo. Sci Adv 10(7):eadk1835 |
| abstractText | The TP53 tumor suppressor gene is mutated early in most of the patients with triple-negative breast cancer (TNBC). The most frequent TP53 alterations are missense mutations that contribute to tumor aggressiveness. Here, we used an autochthonous somatic TNBC mouse model, in which mutant p53 can be toggled on and off genetically while leaving the tumor microenvironment intact and wild-type for p53 to identify physiological dependencies on mutant p53. In TNBCs that develop in this model, deletion of two different hotspot p53R172H and p53R245W mutants triggers ferroptosis in vivo, a cell death mechanism involving iron-dependent lipid peroxidation. Mutant p53 protects cells from ferroptosis inducers, and ferroptosis inhibitors reverse the effects of mutant p53 loss in vivo. Single-cell transcriptomic data revealed that mutant p53 protects cells from undergoing ferroptosis through NRF2-dependent regulation of Mgst3 and Prdx6, which encode two glutathione-dependent peroxidases that detoxify lipid peroxides. Thus, mutant p53 protects TNBCs from ferroptotic death. |
